TapewireFind a company

person · Reporting owner

Beardsley Robert A

Disclosed activity across 2 companies

Tapewire entity
39643
SEC CIK
0001310845

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Arbutus Biopharma CorpABUS · Entity 4953DirectorOctober 01, 2026October 07, 2026
Galera Therapeutics, Inc.GRTX · Entity 15899Chief Operating OfficerFebruary 25, 2023March 01, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arbutus Biopharma Corp

Report date October 01, 2026 · Filed October 07, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect14,328 Reported balance After 2026-10-01 transaction · row 1
1 source row

Row 1 · 2026-10-01 · Disposition to issuer · Disposed 17,948 · Balance 14,328

F1: Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026.

Galera Therapeutics, Inc.

Report date February 25, 2023 · Filed March 01, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.78 · Expires 2033-02-24Direct135,000 Reported balance After 2023-02-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-02-25 · Grant · Acquired 135,000 · Balance 135,000

F1: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 25, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 25, 2023.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
October 01, 2026 Filed Oct 7, 2026 20:12 UTC Arbutus Biopharma Corp ABUS · Entity 4953 Disposition to issuerCommon Shares 17,948 $5.00 $89,740.00
Disclosure

SEC source: 0001447028-26-000061 · wk-form4_1791403925.xml · nonDerivative · entry 1

Beardsley Robert A · CIK 0001310845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,328

F1 · shares: Represents common shares tendered to the Issuer pursuant to the Issuer's tender offer. The Issuer took up and accepted the common shares for payment on October 1, 2026.

Read SEC document
September 18, 2026 Filed Sep 24, 2026 00:31 UTC Arbutus Biopharma Corp ABUS · Entity 4953 Exercise / conversionStock Option (Right to Buy) · Derivative 78,800 $0.00 Strike: $4.24 $0.00
Disclosure

SEC source: 0001447028-26-000050 · wk-form4_1790209858.xml · derivative · entry 5

Beardsley Robert A · CIK 0001310845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 78,800 shares

Expires 2036-06-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option, representing a right to purchase a total of 78,800 shares, was fully vested and exercisable as of the June 8, 2026 grant date.

Read SEC document
September 18, 2026 Filed Sep 24, 2026 00:31 UTC Arbutus Biopharma Corp ABUS · Entity 4953 Exercise / conversionStock Option (Right to Buy) · Derivative 52,533 $0.00 Strike: $3.20 $0.00
Disclosure

SEC source: 0001447028-26-000050 · wk-form4_1790209858.xml · derivative · entry 4

Beardsley Robert A · CIK 0001310845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,067

Underlying: Common Shares · 52,533 shares

Expires 2035-03-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option, representing a right to purchase a total of 157,600 shares, vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd and 3rd anniversaries of the March 18, 2025 grant date, subject to the Reporting Person's continuous service as of each vesting date.

Read SEC document
September 18, 2026 Filed Sep 24, 2026 00:31 UTC Arbutus Biopharma Corp ABUS · Entity 4953 Tax withholdingCommon Shares 99,057 $5.07 $502,218.99
Disclosure

SEC source: 0001447028-26-000050 · wk-form4_1790209858.xml · nonDerivative · entry 3

Beardsley Robert A · CIK 0001310845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,276

F1 · kind: The Reporting Person exercised options on September 18, 2026. The Issuer withheld an aggregate of 99,057 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices.

Read SEC document
September 18, 2026 Filed Sep 24, 2026 00:31 UTC Arbutus Biopharma Corp ABUS · Entity 4953 Exercise / conversionCommon Shares 78,800 $4.24 $334,112.00
Disclosure

SEC source: 0001447028-26-000050 · wk-form4_1790209858.xml · nonDerivative · entry 2

Beardsley Robert A · CIK 0001310845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 18, 2026 Filed Sep 24, 2026 00:31 UTC Arbutus Biopharma Corp ABUS · Entity 4953 Exercise / conversionCommon Shares 52,533 $3.20 $168,105.60
Disclosure

SEC source: 0001447028-26-000050 · wk-form4_1790209858.xml · nonDerivative · entry 1

Beardsley Robert A · CIK 0001310845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,533

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 08, 2026 Filed Jun 10, 2026 20:05 UTC Arbutus Biopharma Corp ABUS · Entity 4953 GrantStock Option (Right to Buy) · Derivative 78,800 $0.00 Strike: $4.24 $0.00
Disclosure

SEC source: 0001447028-26-000039 · wk-form4_1781121921.xml · derivative · entry 1

Beardsley Robert A · CIK 0001310845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,800

Underlying: Common Shares · 78,800 shares

Expires 2036-06-08

F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.

F2 · derivative.exercise_date: The option is fully vested and exercisable as of the date of the grant.

Read SEC document
March 18, 2025 Filed Mar 20, 2025 20:10 UTC Arbutus Biopharma Corp ABUS · Entity 4953 GrantStock Option (Right to Buy) · Derivative 157,600 $0.00 Strike: $3.20 $0.00
Disclosure

SEC source: 0001447028-25-000075 · wk-form4_1742501408.xml · derivative · entry 1

Beardsley Robert A · CIK 0001310845 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,600

Underlying: Common Shares · 157,600 shares

Expires 2035-03-18

F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.

F2 · derivative.exercise_date: This option vests over a three-year period, with 1/3rd of the total shares subject to the option vesting at each of the 1st, 2nd, and 3rd anniversaries of the grant date, subject to the Reporting Person's continuous service as of each vesting date.

Read SEC document
February 25, 2023 Filed Mar 1, 2023 00:06 UTC Galera Therapeutics, Inc. GRTX · Entity 15899 GrantStock Option (Right to Buy) · Derivative 135,000 $0.00 Strike: $1.78 $0.00
Disclosure

SEC source: 0000899243-23-006475 · doc4.xml · derivative · entry 1

Beardsley Robert A · CIK 0001310845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2033-02-24

F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 25, 2023.

Read SEC document
November 21, 2022 Filed Nov 22, 2022 21:05 UTC Galera Therapeutics, Inc. GRTX · Entity 15899 Exercise / conversionStock Option · Derivative 10,000 $0.00 Strike: $1.07 $0.00
Disclosure

SEC source: 0000899243-22-036697 · doc4.xml · derivative · entry 2

Beardsley Robert A · CIK 0001310845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,651

Underlying: Common Stock · 10,000 shares

Expires 2022-11-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option has fully vested and is currently exercisable.

Read SEC document
November 21, 2022 Filed Nov 22, 2022 21:05 UTC Galera Therapeutics, Inc. GRTX · Entity 15899 Exercise / conversionCommon Stock 10,000 $1.07 $10,700.00
Disclosure

SEC source: 0000899243-22-036697 · doc4.xml · nonDerivative · entry 1

Beardsley Robert A · CIK 0001310845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,191

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
September 12, 2022 Filed Sep 13, 2022 20:10 UTC Galera Therapeutics, Inc. GRTX · Entity 15899 Exercise / conversionStock Option · Derivative 10,000 $0.00 Strike: $1.07 $0.00
Disclosure

SEC source: 0000899243-22-030911 · doc4.xml · derivative · entry 2

Beardsley Robert A · CIK 0001310845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,651

Underlying: Common Stock · 10,000 shares

Expires 2022-11-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option has fully vested and is currently exercisable.

Read SEC document
September 12, 2022 Filed Sep 13, 2022 20:10 UTC Galera Therapeutics, Inc. GRTX · Entity 15899 Exercise / conversionCommon Stock 10,000 $1.07 $10,700.00
Disclosure

SEC source: 0000899243-22-030911 · doc4.xml · nonDerivative · entry 1

Beardsley Robert A · CIK 0001310845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,191

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 28, 2022 Filed Mar 2, 2022 21:06 UTC Galera Therapeutics, Inc. GRTX · Entity 15899 GrantStock Option (Right to Buy) · Derivative 75,000 $0.00 Strike: $2.24 $0.00
Disclosure

SEC source: 0000899243-22-008585 · doc4.xml · derivative · entry 1

Beardsley Robert A · CIK 0001310845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2032-02-27

F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments with the first installment vesting on March 28, 2022.

Read SEC document
December 17, 2021 Filed Dec 20, 2021 23:30 UTC Galera Therapeutics, Inc. GRTX · Entity 15899 Exercise / conversionStock Option · Derivative 20,000 $0.00 Strike: $1.07 $0.00
Disclosure

SEC source: 0000899243-21-049011 · doc4.xml · derivative · entry 2

Beardsley Robert A · CIK 0001310845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,651

Underlying: Common Stock · 20,000 shares

Expires 2022-11-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option has fully vested and is currently exercisable.

Read SEC document
December 17, 2021 Filed Dec 20, 2021 23:30 UTC Galera Therapeutics, Inc. GRTX · Entity 15899 Exercise / conversionCommon Stock 20,000 $1.07 $21,400.00
Disclosure

SEC source: 0000899243-21-049011 · doc4.xml · nonDerivative · entry 1

Beardsley Robert A · CIK 0001310845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,191

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 26, 2021 Filed Jan 28, 2021 21:05 UTC Galera Therapeutics, Inc. GRTX · Entity 15899 GrantStock Option (Right to Buy) · Derivative 75,000 $0.00 Strike: $11.99 $0.00
Disclosure

SEC source: 0000899243-21-003611 · doc4.xml · derivative · entry 1

Beardsley Robert A · CIK 0001310845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2031-01-25

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing January 26, 2021.

Read SEC document
January 31, 2020 Filed Feb 4, 2020 23:00 UTC Galera Therapeutics, Inc. GRTX · Entity 15899 GrantStock Option (Right to Buy) · Derivative 74,435 $0.00 Strike: $14.84 $0.00
Disclosure

SEC source: 0000899243-20-002866 · doc4.xml · derivative · entry 1

Beardsley Robert A · CIK 0001310845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,435

Underlying: Common Stock · 74,435 shares

Expires 2030-01-30

F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four year period commencing January 31, 2020.

Read SEC document
November 12, 2019 Filed Nov 12, 2019 21:15 UTC Galera Therapeutics, Inc. GRTX · Entity 15899 ConversionSeries C Preferred Stock · Derivative 6,774 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-027114 · doc4.xml · derivative · entry 4

Beardsley Robert A · CIK 0001310845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,339 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.

Read SEC document
November 12, 2019 Filed Nov 12, 2019 21:15 UTC Galera Therapeutics, Inc. GRTX · Entity 15899 ConversionSeries B Preferred Stock · Derivative 2,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-027114 · doc4.xml · derivative · entry 3

Beardsley Robert A · CIK 0001310845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 395 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.

Read SEC document
November 12, 2019 Filed Nov 12, 2019 21:15 UTC Galera Therapeutics, Inc. GRTX · Entity 15899 ConversionSeries A Preferred Stock · Derivative 68,907 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-027114 · doc4.xml · derivative · entry 2

Beardsley Robert A · CIK 0001310845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,627 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.

F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.

F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.

Read SEC document
November 12, 2019 Filed Nov 12, 2019 21:15 UTC Galera Therapeutics, Inc. GRTX · Entity 15899 ConversionCommon Stock 15,361 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-027114 · doc4.xml · nonDerivative · entry 1

Beardsley Robert A · CIK 0001310845 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,191

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.

F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.